TY - JOUR AU - Maccio, A. AU - Madeddu, C. AU - Mantovani, G. PY - 2009 DA - 2009// TI - Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: new therapeutic perspectives [J] JO - Obes Rev VL - 10 UR - https://doi.org/10.1111/j.1467-789X.2009.00592.x DO - 10.1111/j.1467-789X.2009.00592.x ID - Maccio2009 ER - TY - JOUR AU - Torre, L. A. AU - Bray, F. AU - Siegel, R. L. PY - 2015 DA - 2015// TI - Global cancer statistics, 2012[J] JO - CA Cancer J Clin VL - 65 UR - https://doi.org/10.3322/caac.21262 DO - 10.3322/caac.21262 ID - Torre2015 ER - TY - JOUR AU - Su, M. AU - Huang, C. X. AU - Dai, A. P. PY - 2016 DA - 2016// TI - Immune checkpoint inhibitors: therapeutic tools for breast Cancer[J] JO - Asian Pac J Cancer Prev VL - 17 UR - https://doi.org/10.7314/APJCP.2016.17.3.905 DO - 10.7314/APJCP.2016.17.3.905 ID - Su2016 ER - TY - JOUR AU - Brahmer, J. R. AU - Tykodi, S. S. AU - Chow, L. Q. PY - 2012 DA - 2012// TI - Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J] JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1200694 DO - 10.1056/NEJMoa1200694 ID - Brahmer2012 ER - TY - JOUR AU - Hodi, F. S. AU - O'Day, S. J. AU - Mcdermott, D. F. PY - 2010 DA - 2010// TI - Improved survival with ipilimumab in patients with metastatic melanoma[J] JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa1003466 DO - 10.1056/NEJMoa1003466 ID - Hodi2010 ER - TY - JOUR AU - Bedognetti, D. AU - Maccalli, C. AU - Bader, S. B. PY - 2016 DA - 2016// TI - Checkpoint inhibitors and their application in breast Cancer[J] JO - Breast Care (Basel) VL - 11 UR - https://doi.org/10.1159/000445335 DO - 10.1159/000445335 ID - Bedognetti2016 ER - TY - JOUR AU - Migali, C. AU - Milano, M. AU - Trapani, D. PY - 2016 DA - 2016// TI - Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond[J] JO - Ther Adv Med Oncol VL - 8 UR - https://doi.org/10.1177/1758834016658423 DO - 10.1177/1758834016658423 ID - Migali2016 ER - TY - JOUR PY - 2016 DA - 2016// JO - Cancer Discov VL - 6 UR - https://doi.org/10.1158/2159-8290.CD-NB2016-049 DO - 10.1158/2159-8290.CD-NB2016-049 ID - ref8 ER - TY - JOUR AU - Mann, J. E. AU - Hoesli, R. AU - Michmerhuizen, N. L. PY - 2017 DA - 2017// TI - Surveilling the potential for precision medicine-driven PD-1/PD-L1-targeted therapy in HNSCC[J] JO - J Cancer VL - 8 UR - https://doi.org/10.7150/jca.17547 DO - 10.7150/jca.17547 ID - Mann2017 ER - TY - JOUR AU - Melani, C. AU - Sangaletti, S. AU - Barazzetta, F. M. PY - 2007 DA - 2007// TI - Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma[J] JO - Cancer Res VL - 67 UR - https://doi.org/10.1158/0008-5472.CAN-07-1882 DO - 10.1158/0008-5472.CAN-07-1882 ID - Melani2007 ER - TY - JOUR AU - Yamada, J. AU - Tsuno, N. H. AU - Kitayama, J. PY - 2009 DA - 2009// TI - Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation[J] JO - J Surg Res VL - 151 UR - https://doi.org/10.1016/j.jss.2008.01.031 DO - 10.1016/j.jss.2008.01.031 ID - Yamada2009 ER - TY - JOUR AU - Coscia, M. AU - Quaglino, E. AU - Iezzi, M. PY - 2010 DA - 2010// TI - Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway[J] JO - J Cell Mol Med VL - 14 UR - https://doi.org/10.1111/j.1582-4934.2009.00926.x DO - 10.1111/j.1582-4934.2009.00926.x ID - Coscia2010 ER - TY - STD TI - Comito G, Segura CP, Taddei ML, et al. Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts[J]. Oncotarget. 2016; ID - ref13 ER - TY - JOUR AU - Barrett-Lee, P. AU - Casbard, A. AU - Abraham, J. PY - 2014 DA - 2014// TI - Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial[J] JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(13)70539-4 DO - 10.1016/S1470-2045(13)70539-4 ID - Barrett-Lee2014 ER - TY - JOUR AU - Coleman, R. AU - Cameron, D. AU - Dodwell, D. PY - 2014 DA - 2014// TI - Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial[J] JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70302-X DO - 10.1016/S1470-2045(14)70302-X ID - Coleman2014 ER - TY - JOUR AU - Jia, X. H. AU - Du, Y. AU - Mao, D. PY - 2015 DA - 2015// TI - Zoledronic acid prevents the tumor-promoting effects of mesenchymal stem cells via MCP-1 dependent recruitment of macrophages[J] JO - Oncotarget VL - 6 UR - https://doi.org/10.18632/oncotarget.4658 DO - 10.18632/oncotarget.4658 ID - Jia2015 ER - TY - JOUR AU - Wang, L. AU - Su, W. AU - Liu, Z. PY - 2012 DA - 2012// TI - CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma[J] JO - Biomaterials VL - 33 UR - https://doi.org/10.1016/j.biomaterials.2012.03.067 DO - 10.1016/j.biomaterials.2012.03.067 ID - Wang2012 ER - TY - JOUR AU - Latchman, Y. AU - Wood, C. R. AU - Chernova, T. PY - 2001 DA - 2001// TI - PD-L2 is a second ligand for PD-1 and inhibits T cell activation[J] JO - Nat Immunol VL - 2 UR - https://doi.org/10.1038/85330 DO - 10.1038/85330 ID - Latchman2001 ER - TY - JOUR AU - Kitazawa, Y. AU - Fujino, M. AU - Wang, Q. PY - 2007 DA - 2007// TI - Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses[J] JO - Transplantation VL - 83 UR - https://doi.org/10.1097/01.tp.0000256293.90270.e8 DO - 10.1097/01.tp.0000256293.90270.e8 ID - Kitazawa2007 ER - TY - JOUR AU - Ren, H. T. AU - Li, Y. M. AU - Wang, X. J. PY - 2016 DA - 2016// TI - PD-1 rs2227982 polymorphism is associated with the decreased risk of breast Cancer in northwest Chinese women: a hospital-based observational study[J] JO - Medicine (Baltimore) VL - 95 UR - https://doi.org/10.1097/MD.0000000000003760 DO - 10.1097/MD.0000000000003760 ID - Ren2016 ER - TY - JOUR AU - Kanda, S. AU - Goto, K. AU - Shiraishi, H. PY - 2016 DA - 2016// TI - Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study[J] JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdw416 DO - 10.1093/annonc/mdw416 ID - Kanda2016 ER - TY - JOUR AU - Iwai, Y. AU - Hemmi, H. AU - Mizenina, O. AU - Kuroda, S. AU - Suda, K. AU - Steinman, R. M. PY - 2008 DA - 2008// TI - An IFN-gamma-IL-18 signaling loop accelerates memory CD8+ T cell proliferation JO - PLoS One VL - 3 UR - https://doi.org/10.1371/journal.pone.0002404 DO - 10.1371/journal.pone.0002404 ID - Iwai2008 ER - TY - JOUR AU - Kuroda, J. AU - Kimura, S. AU - Segawa, H. PY - 2003 DA - 2003// TI - The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate[J] JO - Blood VL - 102 UR - https://doi.org/10.1182/blood-2003-01-0305 DO - 10.1182/blood-2003-01-0305 ID - Kuroda2003 ER - TY - JOUR AU - Hiraga, T. AU - Williams, P. J. AU - Ueda, A. PY - 2004 DA - 2004// TI - Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model[J] JO - Clin Cancer Res VL - 10 UR - https://doi.org/10.1158/1078-0432.CCR-03-0325 DO - 10.1158/1078-0432.CCR-03-0325 ID - Hiraga2004 ER -